Drew Deniger

Drew Deniger

Company: Alaunos Therapeutics

Job title: VP, Research & Development


Targeting Solid Tumors Using Neoantigen-Specific TCR-T Cells 1:30 pm

• Ziopharm’s proprietary neoantigen-reactive TCR discovery platform • Translation of TCR-T cells to the clinic for the treatment of solid tumors • Next generation TCR-T cells co-expressing membrane-bound interleukin-15Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.